Viking Therapeutics: Development Of VK2735 Continues, Buyout Or Not

Viking Therapeutics (NASDAQ: VKTX ) is down nearly 50% since it reported phase 1 data from a trial of oral VK2735 in obese/overweight patients in April 2024. I rated VKTX a buy at that time , as I believedScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disclosure: I/we have no stock, option or si ...